![Anthony A. McKinney](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Anthony A. McKinney
Founder at Ethismos Research, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Kimberly Nearing | F | - |
Ethismos Research, Inc.
![]() Ethismos Research, Inc. BiotechnologyHealth Technology Ethismos Research, Inc. is a clinical-stage drug development company located in an undisclosed location. Ethismos is developing pharmaceutical treatments for pain, depression, and substance use disorders. Amitifadine is different from opioids and addiction treatments because it is not believed to be addictive, nor is it a stimulant or an opioid. Ethismos plans to commence phase 2 amitifadine clinical trials for opioid-sparing and facilitation of opioid taper as a non-opioid analgesic in chronic pain patients treated with long-term opioids. The American company is also exploring amitifadine trials in depression maintenance post-ketamine treatment, methamphetamine dependence, and nicotine cessation. The private company was founded by Anthony A. McKinney and he has been the CEO since incorporation. The company is continuing the development of the patented small molecule, amitifadine, a triple reuptake inhibitor, originally developed by euthymics bioscience, and acquired by ethismos in 2017. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
John Crowley | M | 57 |
Genzyme Therapeutics Ltd.
![]() Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | 4 years |
Dennis D. Kim | M | 54 | 3 years | |
Franklin P. Bymaster | M | 78 |
Neurovance, Inc.
![]() Neurovance, Inc. Miscellaneous Commercial ServicesCommercial Services Neurovance, Inc. operates as a a biopharmaceutical company. It develops treatments for central nervous system disorders. The company was founded by Anthony McKinney and Franklin P. Bymaster in 2011 and is headquartered in Cambridge, MA. | 2 years |
Timothy Barberich | M | 76 |
Neurovance, Inc.
![]() Neurovance, Inc. Miscellaneous Commercial ServicesCommercial Services Neurovance, Inc. operates as a a biopharmaceutical company. It develops treatments for central nervous system disorders. The company was founded by Anthony McKinney and Franklin P. Bymaster in 2011 and is headquartered in Cambridge, MA. | 6 years |
Michael Powell | M | 69 | 8 years | |
Louis C. Bock | M | 59 | 13 years | |
Dan Turner | M | 62 | 7 years | |
Brian H. Dovey | M | 83 | 14 years | |
Joseph Lacob | M | 68 | 8 years | |
Heather Turner | F | 51 | 8 years | |
Ronald P. Landbloom | M | 77 | - | |
Graham Cooper | M | 54 | 5 years | |
Gary D. Tollefson | M | 72 | 3 years | |
Michael A. Cowley | M | 55 | 2 years | |
Patricia Bitar | F | 65 | 2 years | |
Brigitte Robertson | M | - |
Neurovance, Inc.
![]() Neurovance, Inc. Miscellaneous Commercial ServicesCommercial Services Neurovance, Inc. operates as a a biopharmaceutical company. It develops treatments for central nervous system disorders. The company was founded by Anthony McKinney and Franklin P. Bymaster in 2011 and is headquartered in Cambridge, MA. | 1 years |
Julie Smith | F | 53 |
Novazyme Pharmaceuticals, Inc.
![]() Novazyme Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Novazyme Pharmaceuticals, Inc. researches and develops methods for modifying recombinantly produced enzymes. It develops a series of novel protein engineering technologies that have been shown in pre-clinical studies to greatly enhance the targeting and uptake of replacement enzymes. Novazyme's technologies also have application for developing advanced monoclonal antibodies and gene therapies. The company is located in Oklahoma City, OK. | 1 years |
Ian Scott | M | - |
Encysive Pharmaceuticals, Inc.
![]() Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX. | 7 years |
Carol A. Baum | F | 65 | - | |
Walter Piskorski | M | 75 | - | |
Dan Omstead | M | 71 |
Neurovance, Inc.
![]() Neurovance, Inc. Miscellaneous Commercial ServicesCommercial Services Neurovance, Inc. operates as a a biopharmaceutical company. It develops treatments for central nervous system disorders. The company was founded by Anthony McKinney and Franklin P. Bymaster in 2011 and is headquartered in Cambridge, MA. | 2 years |
William J. Fallon | M | - |
Novazyme Pharmaceuticals, Inc.
![]() Novazyme Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Novazyme Pharmaceuticals, Inc. researches and develops methods for modifying recombinantly produced enzymes. It develops a series of novel protein engineering technologies that have been shown in pre-clinical studies to greatly enhance the targeting and uptake of replacement enzymes. Novazyme's technologies also have application for developing advanced monoclonal antibodies and gene therapies. The company is located in Oklahoma City, OK. | 2 years |
James A. Thomson | M | 79 |
Encysive Pharmaceuticals, Inc.
![]() Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX. | 14 years |
John R. Plachetka | M | 70 |
Encysive Pharmaceuticals, Inc.
![]() Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX. | 2 years |
Philip M. Brown | M | 62 |
Encysive Pharmaceuticals, Inc.
![]() Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX. | 5 years |
Eduardo Dunayevich | M | 58 | - | |
Suzanne Oparil | M | 82 |
Encysive Pharmaceuticals, Inc.
![]() Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX. | 9 years |
Ronald J. Anderson | M | 77 |
Encysive Pharmaceuticals, Inc.
![]() Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX. | 11 years |
James C. Lancaster | M | 77 | 2 years | |
Pat O’Sullivan | M | - |
Genzyme Therapeutics Ltd.
![]() Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | 21 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 30 | 96.77% |
United Kingdom | 2 | 6.45% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Anthony A. McKinney
- Personal Network